158 related articles for article (PubMed ID: 15645230)
1. Humoral SPARC/osteonectin protein in plasma cell dyscrasias.
Turk N; Kusec R; Jaksic B; Turk Z
Ann Hematol; 2005 May; 84(5):304-10. PubMed ID: 15645230
[TBL] [Abstract][Full Text] [Related]
2. Highly sensitive detection of melanoma at an early stage based on the increased serum secreted protein acidic and rich in cysteine and glypican-3 levels.
Ikuta Y; Nakatsura T; Kageshita T; Fukushima S; Ito S; Wakamatsu K; Baba H; Nishimura Y
Clin Cancer Res; 2005 Nov; 11(22):8079-88. PubMed ID: 16299239
[TBL] [Abstract][Full Text] [Related]
3. Increased circulating concentrations of the counteradhesive proteins SPARC and thrombospondin-1 in systemic sclerosis (scleroderma). Relationship to platelet and endothelial cell activation.
Macko RF; Gelber AC; Young BA; Lowitt MH; White B; Wigley FM; Goldblum SE
J Rheumatol; 2002 Dec; 29(12):2565-70. PubMed ID: 12465153
[TBL] [Abstract][Full Text] [Related]
4. Elevated serum concentration of hepatocyte growth factor in patients with multiple myeloma: correlation with markers of disease activity.
Alexandrakis MG; Passam FH; Sfiridaki A; Kandidaki E; Roussou P; Kyriakou DS
Am J Hematol; 2003 Apr; 72(4):229-33. PubMed ID: 12666132
[TBL] [Abstract][Full Text] [Related]
5. Serum insulin-like growth factor is not elevated in patients with early B-cell chronic lymphocytic leukemia but is still a prognostic factor for disease progression.
Molica S; Vitelli G; Mirabelli R; Digiesu G; Giannarelli D; Cuneo A; Ribatti D; Vacca A
Eur J Haematol; 2006 Jan; 76(1):51-7. PubMed ID: 16343271
[TBL] [Abstract][Full Text] [Related]
6. Procollagen I amino-terminal propeptide as a potential marker for multiple myeloma.
Kowalska M; Druzd-Sitek A; Fuksiewicz M; Kotowicz B; Chechlinska M; Syczewska M; Walewski J; Kaminska J
Clin Biochem; 2010 Apr; 43(6):604-8. PubMed ID: 20045402
[TBL] [Abstract][Full Text] [Related]
7. The expression of SPARC in adipose tissue and its increased plasma concentration in patients with coronary artery disease.
Takahashi M; Nagaretani H; Funahashi T; Nishizawa H; Maeda N; Kishida K; Kuriyama H; Shimomura I; Maeda K; Hotta K; Ouchi N; Kihara S; Nakamura T; Yamashita S; Matsuzawa Y
Obes Res; 2001 Jul; 9(7):388-93. PubMed ID: 11445660
[TBL] [Abstract][Full Text] [Related]
8. Osteocalcin is not a marker of progress in multiple myeloma. Le Groupe d'Etude et de Recherche sur le Myélome (GERM).
Mejjad O; Le Loët X; Basuyau JP; Ménard JF; Jego P; Grisot C; Daragon A; Grosbois B; Euller-Ziegler L; Monconduit M
Eur J Haematol; 1996; 56(1-2):30-4. PubMed ID: 8599990
[TBL] [Abstract][Full Text] [Related]
9. Aberrant expression of SPARC and its impact on proliferation and apoptosis in ADPKD cyst-lining epithelia.
Wang W; Mei C; Tang B; Zhao H; Xu C; Li Z; Shen X; Fu W; Dai B
Nephrol Dial Transplant; 2006 May; 21(5):1278-88. PubMed ID: 16421164
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical expression of SPARC is correlated with recurrence, survival and malignant potential in meningiomas.
Bozkurt SU; Ayan E; Bolukbasi F; Elmaci I; Pamir N; Sav A
APMIS; 2009 Sep; 117(9):651-9. PubMed ID: 19703125
[TBL] [Abstract][Full Text] [Related]
11. Biochemical markers of bone disease in asymptomatic early stage multiple myeloma. A study on their role in identifying high risk patients.
Corso A; Arcaini L; Mangiacavalli S; Astori C; Orlandi E; Lorenzi A; Passamonti F; Klersy C; Pascutto C; Canevari-Sciorati A; Lazzarino M
Haematologica; 2001 Apr; 86(4):394-8. PubMed ID: 11325645
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of serum neural cell adhesion molecule as a prognostic marker in multiple myeloma.
Poley S; Stieber P; Nüssler V; Pahl H; Fateh-Moghadam A
Anticancer Res; 1997; 17(4B):3021-4. PubMed ID: 9329591
[TBL] [Abstract][Full Text] [Related]
13. Expression of SPARC in tongue carcinoma of stage II is associated with poor prognosis: an immunohistochemical study of 86 cases.
Kato Y; Nagashima Y; Baba Y; Kawano T; Furukawa M; Kubota A; Yanoma S; Imagawa-Ishiguro Y; Satake K; Taguchi T; Hata R; Mochimatsu I; Aoki I; Kameda Y; Inayama Y; Tsukuda M
Int J Mol Med; 2005 Aug; 16(2):263-8. PubMed ID: 16012759
[TBL] [Abstract][Full Text] [Related]
14. Significant overexpression of SPARC/osteonectin mRNA in pancreatic cancer compared to cancer of the papilla of Vater.
Prenzel KL; Warnecke-Eberz U; Xi H; Brabender J; Baldus SE; Bollschweiler E; Gutschow CA; Hölscher AH; Schneider PM
Oncol Rep; 2006 May; 15(5):1397-401. PubMed ID: 16596217
[TBL] [Abstract][Full Text] [Related]
15. High serum level of endostatin in multiple myeloma at diagnosis but not in the plateau phase after treatment.
Urbańska-Ryś H; Robak T
Mediators Inflamm; 2003 Aug; 12(4):229-35. PubMed ID: 14514474
[TBL] [Abstract][Full Text] [Related]
16. [Expression and clinical significance of beta-catenin in multiple myeloma].
Li J; Zhang DB; Luo SK; Zhao Y; Huang BH; Gu JL
Ai Zheng; 2007 Sep; 26(9):1010-4. PubMed ID: 17927863
[TBL] [Abstract][Full Text] [Related]
17. An unexpected inverse correlation between soluble epidermal growth factor receptor and interleukin-6 in metastatic malignant melanoma patients.
Mouawad R; Soubrane C; Rixe O; Khayat D; Spano JP
Melanoma Res; 2006 Aug; 16(4):335-40. PubMed ID: 16845329
[TBL] [Abstract][Full Text] [Related]
18. Staging multiple myeloma patients with active disease using serum levels of beta2m-free HLA class I heavy chain together with IgM or platelet count.
Perosa F; Minoia C; Favoino E; Prete M; Dammacco F
Blood Cells Mol Dis; 2009; 42(1):71-6. PubMed ID: 18996035
[TBL] [Abstract][Full Text] [Related]
19. Soluble c-Met in serum of patients with multiple myeloma: correlation with clinical parameters.
Wader KF; Fagerli UM; Holt RU; Børset M; Sundan A; Waage A
Eur J Haematol; 2011 Nov; 87(5):394-9. PubMed ID: 21466586
[TBL] [Abstract][Full Text] [Related]
20. Clinical significance of telomerase activity in multiple myeloma.
Shiratsuchi M; Muta K; Abe Y; Motomura S; Taguchi F; Takatsuki H; Uike N; Umemura T; Nawata H; Nishimura J
Cancer; 2002 Apr; 94(8):2232-8. PubMed ID: 12001122
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
